March 30

Innovate to accelerate. Blue-sky thinking hub.

Broughton Nicotine Services Chief Regulatory Officer, Dr Nveed Chaudhary announces the launch of our Blue-sky thinking hub aimed at nicotine, pharmaceutical, and cannabis industries.

Nveed discusses the importance of accelerating next generation products to market through sustainable partnerships that help clients turn their innovations into market value.

Innovation to market value

We are excited to announce the launch of our new Blue-sky thinking hub. At Broughton Nicotine Services, we like to think differently. Like science, the world is ever changing and evolving and at the heart of this evolution lies innovation. To achieve total harm reduction, helping smokers to quit while protecting our planet and future generations, manufacturers need to work with innovative partners to meet regulatory obligations, help shape future regulation and deliver future market value. Whether advancing existing technologies or developing new, our goal is simple, to accelerate next generation products to market, advancing a smoke-free future.

What is the Blue-sky thinking hub?

In nicotine, pharmaceutical, and cannabis industries there are current and future global industry challenges to achieve total harm reduction and wellbeing targets. To achieve short-term goals and ensure sustainability for the future, we need to act together now to make a difference. Our open innovation community is based on value creation through collaboration to build sustainable partnerships within these industries. Knowledge inputs and outputs are invaluable to accelerate innovation to advance future technologies in an agile environment. 

What's your innovation?

If you have an idea in any of the following areas, we would like to hear from you:

  • Novel active delivery
  • Formulations
  • Plastics
  • Heating
  • Technology
  • Power
  • Regulations

Innovate to accelerate!

Through collaboration, wouldn't it be fantastic to develop the next big thing, whatever guise that may be in. Developing new technologies in areas such as software applications, environmentally friendly plastics, alternative power sources to batteries, sustainable packaging, and novel routes of delivery will deliver ground-breaking advances in science. Who knows – we could even help influence/shape future policy. We welcome expert knowledge from around the globe to stimulate healthy debate amongst industry professionals. Let's collaborate, innovate, and accelerate the pathway to success - together we can make a difference.

Learn more by clicking the box below:


New call-to-action


Can we help you?

Broughton Nicotine Services have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; advancing a smoke-free future.

Book a meeting with us today to discuss your requirements.


About the Author

Dr Nveed Chaudhary is Chief Regulatory Officer at Broughton Nicotine Services. He has over 15 years of experience in the Next Generation Nicotine Products (NGPs) industry. His educational background includes a Double Hons Degree in Pharmacology and Physiology from University College London and a PhD in Respiratory Molecular Medicine from the University of Southampton. His goal has always been to reduce the burden that lung disease has on patients, society, and public health. Early in his career he worked for the pharmaceutical industry and at Boehringer Ingelheim was the co-inventor of a novel drug for the treatment of idiopathic pulmonary fibrosis, nintedanib esylate, which received regulatory approval in 2014/15. Since 2006, Nveed had worked at three of the largest tobacco companies in the World, focused on the assessment and subsequent regulatory filing of NGPs, including e-cigarettes, heated tobacco products and modern oral nicotine products. His experience at British American Tobacco and Philip Morris International included leading multi-disciplinary, globally based teams on both pre-clinical and clinical assessment of NGPs. Later in his career at Philip Morris International, Nveed was Director of Strategic Communications, with a focus on Tobacco Harm Reduction (THR). In this role, as well as creating narratives around THR for regulatory and key opinion leader engagement, he also had a critical role in creating the narratives for the Premarket Tobacco Product Applications (PMTA) and Modified Risk Tobacco Product (MRTP) applications for IQOS. Most recently, Nveed directed the PMTA programme at Imperial Brands ensuring the timely submission of PMTA applications to support Imperial Brand’s range of deemed products in the USA. Nveed is a true pioneer for NGPs and has worked collaboratively with FDA in the submission of both PMTAs and MRTPs as well as having heavy involvement in PMTAs for both e-vapor and heated tobacco products. As a scientist and communicator, Nveed is passionate about story-telling and using scientific data to underpin the narratives of both regulatory submissions and tobacco harm reduction.